This report focuses on the analytical validity, clinical validity, and clinical utility of the 4Kscore Test to aid in prostate cancer biopsy decision making for physician and patient through: (1) estimating a patient’s percentage of risk for aggressive (Gleason ≥ 7) prostate cancer if a prostate biopsy were performed; and (2) providing information on the 10-year likelihood of…
Publications
Hayes Publications are available through the Hayes Knowledge Center, a portal to world-class research and unbiased analyses on the clinical, financial, and risk impacts of emerging, controversial, and disruptive healthcare technologies.Every Hayes publication is developed by multidisciplinary teams of clinicians and scientists using rigorous methods grounded in internally recognized standards for systematic review and Health Technology Assessment. Learn more about these evidence resources and see sample titles below.
See below for some of our recent publications.
Endolumenal Functional Lumen Imaging Probe (EndoFLIP; Medtronic Inc.) for Evaluation of Esophageal and Gastric Disorders
Health Problem: The esophageal and gastric disorders most frequently evaluated with the Endolumenal Functional Lumen Imaging Probe (EndoFLIP) are achalasia, eosinophilic esophagitis (EE), and gastroparesis, but these disorders are relatively rare, with prevalence ranging from approximately 11 to 52 cases per 100,000 persons in the general population. Disorders of esophage…
Platelet-Rich Plasma for Hip Osteoarthritis
Health Problem: Osteoarthritis (OA) is a painful condition that occurs when the cartilage between the bones degenerates, no longer providing a smooth, gliding surface for motion or adequate cushioning. Damaged articular cartilage does not tend to heal and may progressively worsen and cause focal lesions and eventually OA. Hip OA is common. The estimated lifetime risk for …
FoundationOne Liquid (Foundation Medicine Inc.)
This report evaluates the analytical validity, clinical validity, and clinical utility of the FoundationOne Liquid test.
Polivy (Polatuzumab Vedotin-piiq) for Diffuse Large B-Cell Lymphoma
Polivy (polituzumab-vedotin-piiq) is an intravenously administered CD79b-directed antibody-drug conjugate indicated in combination with a rituximab product and bendamustine for adult patients with relapsed/refractory diffuse large B-cell lymphoma after at least 2 prior therapies.
Polivy (Polatuzumab Vedotin-piiq) for Diffuse Large B-Cell Lymphoma
Polivy (polituzumab-vedotin-piiq) is an intravenously administered CD79b-directed antibody-drug conjugate indicated in combination with a rituximab product and bendamustine for adult patients with relapsed/refractory diffuse large B-cell lymphoma after at least 2 prior therapies.
Comparative Effectiveness Review of Radioactive Yttrium-90 Microspheres for Treatment of Primary Unresectable Liver Cancer
Health Problem: Hepatocellular carcinoma (HCC) is the most common liver malignancy in the United States, accounting for approximately 90% of primary liver cancers. The definitive therapies for HCC are surgical resection, tumor ablation, and liver transplantation; however, most patients are not eligible for these therapies due to the overall burden or severity of their dis…
Comparative Effectiveness Review of Mini Gastric Bypass–One Anastomosis Gastric Bypass for the Treatment of Obesity: A Review of Reviews
Health Problem: Obesity is a common condition in the United States, where approximately 37.7% of adults aged 20 years and older are considered obese. Data from 2013 to 2014 show a rate of obesity of 17.2% among younger individuals aged 2 to 19 years. Morbid obesity is associated with substantively elevated morbidity and mortality due to comorbid conditions, including type…
Tegsedi (Inotersen) for Hereditary Transthyretin Amyloidosis
Tegsedi (inotersen) is an antisense oligonucleotide (ASO) that inhibits production of transthyretin that is intended for the treatment of polyneuropathy due to hereditary transthyretin (TTR) amyloidosis. Inotersen is administered weekly via subcutaneous injection.
Tegsedi (Inotersen) for Hereditary Transthyretin Amyloidosis
Tegsedi (inotersen) is an antisense oligonucleotide (ASO) that inhibits production of transthyretin that is intended for the treatment of polyneuropathy due to hereditary transthyretin (TTR) amyloidosis. Inotersen is administered weekly via subcutaneous injection.